Immunotherapy using immune checkpoint blockade (ICB), such as anti-CTLA4 and anti-PD1 antibodies, has revolutionized cancer treatment and has generated durable therapeutic responses in a significant subset of patients across a variety of cancer types. Here, CTLA4 is linked to cancer.